Patient-friendly summary
If you read nothing else
Bottom line
Across nine high-quality guidelines, NSAIDs are the most consistently recommended first-line medication for acute and chronic low back pain, while corticosteroids, benzodiazepines, anticonvulsants, and antibiotics are recommended by none; most other drug classes show substantial disagreement reflecting limited high-quality evidence.
Moderate evidencePublished
Evidence hierarchy
Study participants
Clinical practice guidelines on non-specific/mechanical low back pain published 2015-2020, with global representation
Study Summary
This systematic review identified and compared the medication recommendations of nine high-quality clinical practice guidelines (CPGs) published between 2015 and 2020 for the management of non-specific (mechanical) low back pain. Across the guidelines, ten medication classes were addressed. NSAIDs emerged as the most consistently recommended first-line drug therapy for both acute and chronic low back pain, while acetaminophen and skeletal muscle relaxants were recommended inconsistently for acute pain, and acetaminophen and antidepressants (notably duloxetine) were proposed with less consensus as second-line options for chronic pain. No guideline recommended oral corticosteroids, benzodiazepines, anticonvulsants, or antibiotics, and recommendations within many drug classes were highly heterogeneous, reflecting limited high-quality evidence and reliance on expert opinion.
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| NSAIDs were the most frequently recommended medication, endorsed as first-line therapy | Nine guidelines addressed NSAIDs and 8 of 9 recommended them. They were the first pharmacological choice for acute LBP in one CPG and for chronic LBP in two CPGs. Most guidelines advised the lowest effective dose for the shortest period, and seven discussed gastrointestinal, cardiovascular, renal, and/or hepatic risks. | High |
| Several medication classes were recommended by no guideline | Oral corticosteroids, benzodiazepines, anticonvulsants (e.g., gabapentin, pregabalin), and antibiotics were not recommended by any of the included CPGs for acute or chronic LBP, generally due to insufficient evidence and/or unfavorable harm profiles. | High |
| Acetaminophen and skeletal muscle relaxants were inconsistently recommended for acute LBP | Of 8 CPGs reviewing acetaminophen, only 3 recommended it (with 4 recommending against and 1 inconclusive). Of 7 CPGs reviewing SMRs, 5 recommended them for acute LBP, but strength ranged from strong against for all durations to strong for as a first-line acute choice; SMR use was generally advised for less than 1-2 weeks. | Medium |
| Antidepressants (duloxetine) had limited, second-line support for chronic LBP | Three of seven CPGs gave a weak recommendation in favor of duloxetine as a second-line option for chronic LBP, while others recommended against routine antidepressant use; tricyclics were suggested as a third-line option in one CPG. Antidepressants were not recommended for acute LBP. | Medium |
| Opioids and atypical opioids (tramadol) were recommended only with caution and short-term | All nine CPGs discussed opioids; five considered them for acute LBP only with caution, short-term, and after other treatments failed, while three recommended against all opioids. Tramadol was separated as an atypical opioid by three CPGs, with two suggesting it as a later-line consideration for chronic LBP after other interventions failed. | Medium |
| Guideline quality was high but recommendations were heterogeneous | The mean overall AGREE II score was 89.3% (SD 3.5%); eight of nine guidelines were rated high-quality and one low-quality. Despite high methodological quality, recommendations varied widely within drug classes, attributed to limited high-quality RCT evidence and reliance on expert opinion, harm-benefit balancing, and cost/accessibility considerations. | High |
Nine guidelines addressed NSAIDs and 8 of 9 recommended them. They were the first pharmacological choice for acute LBP in one CPG and for chronic LBP in two CPGs. Most guidelines advised the lowest effective dose for the shortest period, and seven discussed gastrointestinal, cardiovascular, renal, and/or hepatic risks.
Oral corticosteroids, benzodiazepines, anticonvulsants (e.g., gabapentin, pregabalin), and antibiotics were not recommended by any of the included CPGs for acute or chronic LBP, generally due to insufficient evidence and/or unfavorable harm profiles.
Of 8 CPGs reviewing acetaminophen, only 3 recommended it (with 4 recommending against and 1 inconclusive). Of 7 CPGs reviewing SMRs, 5 recommended them for acute LBP, but strength ranged from strong against for all durations to strong for as a first-line acute choice; SMR use was generally advised for less than 1-2 weeks.
Three of seven CPGs gave a weak recommendation in favor of duloxetine as a second-line option for chronic LBP, while others recommended against routine antidepressant use; tricyclics were suggested as a third-line option in one CPG. Antidepressants were not recommended for acute LBP.
All nine CPGs discussed opioids; five considered them for acute LBP only with caution, short-term, and after other treatments failed, while three recommended against all opioids. Tramadol was separated as an atypical opioid by three CPGs, with two suggesting it as a later-line consideration for chronic LBP after other interventions failed.
The mean overall AGREE II score was 89.3% (SD 3.5%); eight of nine guidelines were rated high-quality and one low-quality. Despite high methodological quality, recommendations varied widely within drug classes, attributed to limited high-quality RCT evidence and reliance on expert opinion, harm-benefit balancing, and cost/accessibility considerations.
Strengths
- Followed PRISMA methodology with independent dual screening, dual data extraction, and a third reviewer for disagreements
- Used the validated AGREE II instrument for critical appraisal, with four independent reviewers who completed standardized training
- Included guidelines were predominantly high methodological quality (mean overall AGREE II 89.3%; eight of nine rated high-quality)
- Provided global representation across multiple countries and health systems
- Transparently discussed the limited and aging evidence base and the role of harm-benefit and cost considerations in guideline variability
Limitations
- Only English-language guidelines were evaluated, potentially excluding insight from non-English CPGs
- Only nine guidelines met inclusion criteria, and systematic reviews and other study designs were excluded
- Included guidelines may have relied on synthesized reviews rather than primary RCTs, possibly perpetuating recommendations lacking high-quality efficacy evidence
- Recommendations are descriptive and heterogeneous; the review does not establish comparative effectiveness of medications
- Much of the underlying evidence (e.g., for antidepressants) was older, with cited RCTs performed between 1976 and 2007 and often not including duloxetine
Key Takeaways for Patients
What This Means for You
- 01For most people with low back pain, anti-inflammatory medications (NSAIDs such as ibuprofen) are the medication that guidelines most consistently recommend first, used at the lowest effective dose for the shortest time.
- 02Many medications people might expect to help, including oral steroids, benzodiazepines (sedatives), nerve-pain drugs like gabapentin/pregabalin, and antibiotics, are not recommended by guidelines for ordinary low back pain.
- 03Acetaminophen (paracetamol) and muscle relaxants are recommended inconsistently; some guidelines suggest them only if other options fail, and evidence that acetaminophen helps back pain is limited.
- 04Opioids, including tramadol, are advised only with caution, for short periods, and usually after other treatments have not worked, because of serious risks.
- 05Medication is only part of the picture; guidelines emphasize staying active, patient education, and non-drug care alongside any medication.
Read the Full Paper
Access the complete peer-reviewed study from Chiropractic & Manual Therapies
View Full Study